Ayrmid appoints Ideogen as exclusive partner for Omisirge in EMEA
Ayrmid appointed Ideogen as its exclusive partner to launch a managed access program for Omisirge across 55 markets spanning Europe, MENA and CIS, covering both FDA-approved Omisirge indications.
Ayrmid Appoints Ideogen as Exclusive Partner for Omisirge® across Multiple Regions in Europe, MENA and CISIdeogen granted exclusive rights to launch a managed access program for Omisirge across 55 markets, covering both FDA-approved Omisirge indicationsDUBLIN, IE / / September 1, 20…